{"Clinical Trial ID": "NCT00256698", "Intervention": ["INTERVENTION 1:", "-Fulvestant + Anastrozole", "Dose regime for loading 250 mg Fulvestant + Anastrozole 1 mg", "INTERVENTION 2:", "Anastrozole", "Anastrozole 1 mg"], "Eligibility": ["Incorporation criteria:", "Signed informed consent, female menopausal, estrogen and/or progesterone (PgR) confirmed histological or cytological, positive breast cancer, local recurrence or metastases", "- Exclusion criteria:", "Previous systemic endocrine treatment for advanced or recurrent disease; previous fulvestant treatment", "Premenopausal women"], "Results": ["Performance measures:", "Time of progression (TTP)", "(RECIST is a set of published rules that define when cancer patients improve their \"responsibility\", remain the same \"stables\" or worsen \"progress\" during treatment.", "Timeline: RECIST evaluations conducted every 8 weeks from randomization to data cut-off on April 30, 2009", "Results 1:", "Title of the arm/group: Fulvestant + Anastrozole", "Description of the arm/group: Fulvestant 250 mg Loading dose regimen + Anastrozole 1 mg", "Total number of participants analysed: 258", "Median (full range)", "Unit of measure: month 10.8 (0 to 49.31)", "Results 2:", "Title of the arm/group: Anastrozole", "Description of the arm/group: Anastrozole 1 mg", "Total number of participants analysed: 256", "Median (full range)", "Unit of measure: month 10.2 (0 to 54.34)"], "Adverse Events": ["Undesirable Events 1:", "Total: 40/256 (15.63 per cent)", "Anemia 1/256 (0.39%)", "Heart failure 3/256 (1.17 per cent)", "Pericardial infusion 0/256 (0.00 %)", "Angine Pectoris 0/256 (0.00 %)", "Arrhythmia 0/256 (0.00 %)", "Atrial flutter 0/256 (0.00 %)", "- Cardiac arrest 0/256 (0.00 %)", "Atrial fibrillation 1/256 (0.39%)", "Bradycardia 1/256 (0.39%)", "Cardiomyopathy 1/256 (0.39%)", "Myocardial infarction 1/256 (0.39%)", "Adverse Events 2:", "Total: 45/254 (17.72 per cent)", "Anemia 1/254 (0.39%)", "- Heart failure 1/254 (0.39%)", "\u2014 Pericardial infusion 2/254 (0.79%)", "Angina Pectoris 1/254 (0.39%)", "Arrhythmia 1/254 (0.39%)", "Atrial stop 1/254 (0.39%)", "- Cardiac arrest 1/254 (0.39%)", "Atrial fibrillation 0/254 (0.00 %)", "Bradycardia 0/254 (0.00 %)", "Cardiomyopathy 0/254 (0.00 %)", "Myocardial infarction 0/254 (0.00 %)"]}